Which statement NOT an obligation in pharmacovigilance programs?

Which statement NOT an obligation in pharmacovigilance programs?

• A. Timely Reporting to Regulators and Manufacturers
• B. Contributing to Post-Market Surveillance
• C. Mandatory Personal Medical Privacy Waivers
• D. Providing Safety Updates

Answer: (C)

Pharmacovigilance is about ensuring patient safety through systematic monitoring and communication of drug-related risks, while strictly protecting patient privacy. The obligations center on timely reporting of adverse events to regulators and manufacturers so authorities can assess risk and take action; ongoing post-market surveillance to gather real-world safety data; and providing safety updates to healthcare professionals and patients to keep everyone informed and guide risk management decisions. A blanket requirement for mandatory personal medical privacy waivers does not fit this framework. Protecting privacy is a fundamental principle in handling health data; data used for safety monitoring is typically de-identified or handled under strict consent and data-protection rules. Requiring a privacy waiver would undermine confidentiality and violate data-protection norms, so it is not an obligation in pharmacovigilance programs.

Pharmacovigilance is about ensuring patient safety through systematic monitoring and communication of drug-related risks, while strictly protecting patient privacy. The obligations center on timely reporting of adverse events to regulators and manufacturers so authorities can assess risk and take action; ongoing post-market surveillance to gather real-world safety data; and providing safety updates to healthcare professionals and patients to keep everyone informed and guide risk management decisions. A blanket requirement for mandatory personal medical privacy waivers does not fit this framework. Protecting privacy is a fundamental principle in handling health data; data used for safety monitoring is typically de-identified or handled under strict consent and data-protection rules. Requiring a privacy waiver would undermine confidentiality and violate data-protection norms, so it is not an obligation in pharmacovigilance programs.